Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4872719 | 0.98 | NPSR1 (0.45) | NPSR1CYP4F2CYP4A11MAPTMEN1 | |
| SCHEMBL2305290 | 0.98 | NPSR1 (0.45) | NPSR1CYP4F2CYP4A11MAPTMEN1 | |
| SCHEMBL1971946 | 0.95 | NPSR1 (0.42) | NPSR1CYP4F2CYP4A11MAPTMEN1 | |
| SCHEMBL2547049 | 0.91 | — | — | |
| SCHEMBL4866927 | 0.83 | NPSR1 (0.35) | NPSR1CYP4F2CYP4A11MEN1CYP3A4 | |
| SCHEMBL2289949 | 0.82 | NPSR1 (0.47) | NPSR1CYP4F2CYP4A11MAPTMEN1 | |
| SCHEMBL5113321 | 0.81 | CYP3A4 (0.40) | NPSR1CYP3A4ALDH1A1LMNA | |
| SCHEMBL31711898 | 0.81 | NPSR1 (0.34) | NPSR1LMNA | |
| SCHEMBL2290780 | 0.80 | NPSR1 (0.45) | NPSR1CYP4F2CYP4A11MAPTMEN1 | |
| SCHEMBL11308445 | 0.80 | NPSR1 (0.45) | NPSR1CYP4F2CYP4A11MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5948935-A | Process and intermediates for (s)-α-amino-1-carboxycyclopentaneacetic acid | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 1999-09-07 | — | — | US | claimed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-8816090-B2 | Benzisoxazole derivatives | PFIZER INC. (US) | 2014-08-26 | — | — | US | disclosed |
| EP-1856114-B1 | BENZISOXAZOLE DERIVATIVES | PFIZER (US) | 2014-08-20 | — | — | EP | disclosed |
| US-20080207690-A1 | Benzisoxazole Derivatives | RAQUALIA PHARMA INC. (JP) | 2008-08-28 | — | — | US | disclosed |
| US-7332485-B2 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORP (US) | 2008-02-19 | — | — | US | disclosed |
| EP-1856114-A1 | BENZISOXAZOLE DERIVATIVES | Pfizer, Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006090224-A1 | BENZISOXAZOLE DERIVATIVES | PFIZER JAPAN INC. (JP) | 2006-08-31 | — | — | WO | disclosed |
| US-20060160802-A1 | Peptide deformylase inhibitors | GLAXO GROUP LIMITED | 2006-07-20 | — | — | US | disclosed |
| WO-2005005456-A2 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-01-20 | — | — | WO | disclosed |
| US-5948935-A | Process and intermediates for (s)-α-amino-1-carboxycyclopentaneacetic acid | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 1999-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160802-A1 | Peptide deformylase inhibitors | PDF, PEPD, DPEP1 | NPSR1 3037/4885CYP4F2 4042/4885CYP4A11 4676/4885 |
| US-20080207690-A1 | Benzisoxazole Derivatives | BRS3, MRGPRX4, HTR4 | NPSR1 30/4885CYP4F2 681/4885CYP4A11 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.